相关实验视频

Updated: Jun 12, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

预测谁可能受益于IIB阶段黑色素瘤的辅助免疫治疗

Meredith A Gunder¹, Kyle R Stephens¹, Walter Donica¹

¹The Hiram C. Polk, Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.

American journal of surgery

|June 10, 2025

概括

识别高风险IIB阶段黑色素瘤患者对于辅助免疫治疗决策至关重要. 年龄和线粒速率有效地将患者分为不同的生存组,有助于治疗选择.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
癌症研究癌症研究

背景情况:

辅助免疫疗法已被批准用于IIB阶段黑色素瘤,但具有风险和成本.
识别高风险患者对于明智的辅助治疗决策至关重要.

研究的目的:

为了识别高风险IIB期黑色素瘤患者.
在辅助免疫疗法决策中对患者进行分层.

主要方法:

利用国家癌症数据库 (NCDB) 识别IIB期黑色素瘤患者.
采用考克斯的比例危险模型和条件推断生存树来识别风险因素和组.
使用来自监测,流行病学和最终结果 (SEER) 数据库的黑色素瘤特异性生存数据验证的风险组.

主要成果:

在NCDB中确定了12610名IIB期黑色素瘤患者.
根据年龄和线粒速率 (MR) 确定了三个不同的风险组:年龄<54,年龄≥54,MR ≤3/mm2,年龄≥54,MR >3/mm2.
在SEER数据库中,这些群体的5年黑色素瘤特定死亡率 (12%对15%对20%) 显示出显著差异.

结论:

年龄和线粒速率有效地将IIB期黑色素瘤患者分为不同的预后组.
这些已识别的风险组可以指导临床决定关于辅助治疗.

关键词:

一个辅助的辅助.免疫治疗是一种免疫疗法.黑色素瘤是一种黑色素瘤.幸存的生存方式

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.